Advice
Following a full submission
diclofenac (Dyloject®) is accepted for restricted use within NHS Scotland for the treatment or prevention of post-operative pain by intravenous injection, in supervised healthcare settings.
When given as an intravenous bolus, it showed non-inferiority to a comparator non-steroidal anti-inflammatory drug infusion at providing pain relief over an initial 4 hour period and caused less thrombophlebitis.
The manufacturer’s submission related only to intravenous use of diclofenac (Dyloject®) in the post-operative setting. SMC cannot recommend its use by the intramuscular route.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- diclofenac 75mg/2ml solution for injection (Dyloject)
- SMC ID:
- 446/08
- Indication:
- treatment or prevention of post-operative pain by intravenous injection
- Pharmaceutical company
- Javelin Pharmaceuticals UK Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 March 2008